Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SuppreMol Begins Development of SM401 to Diagnose and Treat RA

Published: Wednesday, July 25, 2012
Last Updated: Tuesday, July 24, 2012
Bookmark and Share
Licensing agreement with the University Hospital of Regensburg.

SuppreMol GmbH has announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA).

SuppreMol will advance preclinical development of SM401 for treatment of RA.

Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

SuppreMol’s preclinical candidate SM401 has demonstrated, in a murine model for RA, that it significantly reduces progression and severity of the disease.

At the same time, levels of the inflammatory cytokines IL-6 and TNF-alpha, which are reduced by several established RA drugs, are also lowered.

Furthermore, it has been demonstrated that IL-3 concentrations were only elevated at the onset of arthritis and fell to low levels during the course of the disease in the animal model.

Using the newly developed IL-3 diagnostic assay, SuppreMol expects to develop a biomarker for the stratification of RA patients.

“This SM401 program advances SuppreMol's strategy to target very early events in the development of autoimmune diseases,” said Dr. Peter Sondermann, CSO and co-founder of SuppreMol GmbH.

Dr. Sondermann continued, “Through this early intervention approach we expect to stop progression of the autoimmune disease rather than simply treating symptoms of inflammation. We expect to begin clinical trials in 2014.”

The anti-IL-3 monoclonal antibody was generated by the group of Professor Dr. Matthias Mack at Regensburg University Hospital - Internal Medicine II, following the discovery that increased levels of IL-3 indicate early onset and activity of RA. Prof. Mack is a member of SuppreMol’s Scientific Advisory Board.

“This licensing agreement with Bayerische Patentallianz GmbH provides SuppreMol a very strong portfolio of autoimmune therapies and a potential companion RA diagnostic,” said Professor Dr. Peter Buckel, CEO of SuppreMol GmbH.

“Along with our Fc gamma receptor platform with three clinical and two further preclinical programs targeting autoimmune diseases and allergies, this SM401 program is another building block in the strong foundation of the company’s future,” he added.

Bayerische Patentallianz GmbH is the central patent and marketing agency of the Bavarian Universities and Universities of Applied Sciences, including the University of Regensburg.

Early development of SM401 is being funded by a grant of € 1.37 million from the German Federal Ministry of Education and Research (BMBF).

The project was funded in Prof. Mack’s laboratory through BayImmuNet, the Bayerisches Immuntherapie Netzwerk; the development of a therapeutic anti-IL-3 antibody including a highly sensitive IL-3 assay is supported by the German Federal Ministry of Education and Research within the Leading-Egde Cluster “m4 - Personalized Medicine and Targeted Therapies” in Munich.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Autism and Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!